Tessellations aren’t just eye-catching patterns—they can be used to crack complex mathematical problems. By repeatedly ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts. Solve Therapeutics’ ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Beijing Zhongke Journal Publising Co. Ltd. The lead author Cheng-Zhi Qin, a professor of geographical information science (GIS) at Institute of Geographic Sciences and Natural Resources Research, ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

The author recounts a personal journey from focusing on astronomy to becoming deeply involved in climate change research, highlighting the disconnect between scientific understanding and societal ...

What's going on with Recursion? Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his ...